CARsgen Announces Formation of its Clinical Advisory Board

ASCO GI Preview | CARsgen to Present Results of CT041 at 2024 ASCO GI

ASH Preview | CARsgen to Present Results of Zevor-cel at 2023 ASH Annual Meeting

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

CARsgen Announced 2023 Interim Results

CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

CARsgen’s CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer